Method for selectively modifying a protein via transglutaminase catalyzed reaction
The present invention relates generally to a novel method of introducing property modifying groups to a protein. In particular, the present invention relates to the derivatization of lysine residues, as well as new conjugates of growth hormones with improved pharmacological properties, and methods for their preparation and use in therapy.
1. A method for site selective modification of a protein, said method comprising: contacting the protein with an auxiliary protein and a property modifying group selected from the group consisting of
2. The method according to claim 1 , wherein the protein subject to site selective modification is a cytokine.
3. The method according to claim 1 , wherein the protein subject to site selective modification belongs to class of 4-helix bundle proteins.
4. The method according to claim 1 , wherein the protein subject to site selective modification is hGH.
5. The method according to claim 1 , wherein the auxiliary protein is an enzyme that modifies glutamine residues.
6. The method according to claim 1 , wherein the auxiliary protein is a transglutaminase.
7. The method according to claim 6 , in which the transglutaminase is microbial transglutaminase from S. mobaraense.
8. The method according to claim 7 , wherein the transglutaminase is a mutant of microbial transglutaminase from S. mobaraense with 80% or more sequence homology relative to native microbial transglutaminase from S. mobaraense.
9. A method for site selective modification of growth hormone, the method comprising contacting growth hormone with an auxiliary protein and a property modifying group selected from the group consisting of
10. The method according to claim 9 , wherein the growth hormone is human growth hormone.
11. The method according to claim 9 , wherein the auxiliary protein is a transglutaminase.
12. The method according to claim 11 , in which the transglutaminase is microbial transglutaminase from S. mobaraense.
13. The method according to claim 12 , wherein the transglutaminase is a mutant of microbial transglutaminase from S. mobaraense with 80% or more sequence homology relative to native microbial transglutaminase from S. mobaraense.
14. The method according to claim 10 , wherein the human growth hormone is modified at a lysine residue.
15. The method according to claim 14 , wherein the human growth hormone is site selectively modified at lysine 145, wherein said lysine 145 corresponds to the amino acid at position 145 of SEQ ID NO:4.
16. The method according to claim 15 , wherein the human growth hormone is site selectively modified at lysine 145 and subsequently conjugated to a protracting group that prolongs the in vivo halflife of the conjugate compared to hGH.
17. The method according to claim 16 , wherein the protracting group is a hydrophilic polymer.
18. The method according to claim 16 , wherein the protracting group is a PEG.
19. The method according to claim 16 , wherein the protracting group contains a moiety that binds reversibly to albumin.
20. The method according to claim 16 , wherein the protracting group contains a fatty acid residue or a fatty diacid residue.